Myriad Genetics (MYGN) Tops Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $3.97 -1%
Revenue Growth %: -7.0%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -7.0%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.03), $0.05 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $191.9 million versus the consensus estimate of $179.23 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- AutoZone beats profit view but misses on revenue
- UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
